Compare Stocks: SILO, QNRX, DARE, and CALC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.98 -6.6%	$3.31	$1.91 ▼ $36.00	$14.48M	0.83	99,195 shs	23,152 shs
DARE Dare Bioscience	$0.71 +0.1%	$1.22	$0.69 ▼ $3.78	$13.87M	1.01	912,093 shs	93,676 shs
QNRX Quoin Pharmaceuticals	$6.79 -1.6%	$5.20	$3.25 ▼ $41.80	$13.86M	1.51	1.67 million shs	65,673 shs
SILO Silo Pharma	$2.10	$3.82	$2.05 ▼ $15.15	$3.34M	0.66	123,113 shs	36,630 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-6.60%	-8.76%	-36.12%	-54.33%	-88.65%
DARE Dare Bioscience	+0.13%	-2.08%	-50.97%	-65.05%	-66.85%
QNRX Quoin Pharmaceuticals	-1.59%	-6.47%	+15.28%	+61.67%	-9.10%
SILO Silo Pharma	0.00%	-12.50%	-32.26%	-68.33%	-78.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.98 -6.6%	$3.31	$1.91 ▼ $36.00	$14.48M	0.83	99,195 shs	23,152 shs
DARE Dare Bioscience	$0.71 +0.1%	$1.22	$0.69 ▼ $3.78	$13.87M	1.01	912,093 shs	93,676 shs
QNRX Quoin Pharmaceuticals	$6.79 -1.6%	$5.20	$3.25 ▼ $41.80	$13.86M	1.51	1.67 million shs	65,673 shs
SILO Silo Pharma	$2.10	$3.82	$2.05 ▼ $15.15	$3.34M	0.66	123,113 shs	36,630 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-6.60%	-8.76%	-36.12%	-54.33%	-88.65%
DARE Dare Bioscience	+0.13%	-2.08%	-50.97%	-65.05%	-66.85%
QNRX Quoin Pharmaceuticals	-1.59%	-6.47%	+15.28%	+61.67%	-9.10%
SILO Silo Pharma	0.00%	-12.50%	-32.26%	-68.33%	-78.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	2.20	Hold	$50.00	2,425.25% Upside
DARE Dare Bioscience	2.33	Hold	$12.00	1,599.72% Upside
QNRX Quoin Pharmaceuticals	2.00	Hold	N/A	N/A
SILO Silo Pharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SILO, QNRX, DARE, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	SILO Silo Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/20/2026	QNRX Quoin Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
DARE Dare Bioscience	$1.03M	13.48	N/A	N/A	$0.20 per share	3.53
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$15.64 per share	N/A
SILO Silo Pharma	$54.08K	61.67	N/A	N/A	$7.10 per share	0.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
QNRX Quoin Pharmaceuticals	-$15.81M	-$25.18	N/A	N/A	N/A	N/A	-489.57%	-221.17%	11/5/2026 (Estimated)
SILO Silo Pharma	-$4.23M	-$4.36	N/A	N/A	N/A	-6,726.39%	-81.75%	-66.35%	N/A

Latest SILO, QNRX, DARE, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	QNRX Quoin Pharmaceuticals	-$1.61	-$1.90	-$0.29	-$1.90	N/A	N/A
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/13/2026	Q2 2026	SILO Silo Pharma	-$0.32	-$0.76	-$0.44	-$0.76	$0.02 million	N/A
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SILO Silo Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.67	5.58	5.58
DARE Dare Bioscience	N/A	0.99	0.99
QNRX Quoin Pharmaceuticals	N/A	1.76	1.76
SILO Silo Pharma	N/A	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
DARE Dare Bioscience	6.70%
QNRX Quoin Pharmaceuticals	8.63%
SILO Silo Pharma	5.58%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	28.25%
DARE Dare Bioscience	4.10%
QNRX Quoin Pharmaceuticals	11.17%
SILO Silo Pharma	3.63%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	30	6.83 million	4.90 million	No Data
DARE Dare Bioscience	30	19.67 million	18.86 million	Not Optionable
QNRX Quoin Pharmaceuticals	4	2.01 million	1.78 million	Not Optionable
SILO Silo Pharma	2	1.59 million	1.53 million	Not Optionable

SILO, QNRX, DARE, and CALC Headlines

Recent News About These Companies

Silo Pharma To Highlight SPC-15 Nose-To-Brain Technology At 2026 Nasal Innovation Forum

September 9 at 12:53 PM | rttnews.com

Silo Pharma to Participate in IPAC-RS 2026 Nasal Innovation Forum as It Advances SPC-15 Development

September 9 at 9:31 AM | quiverquant.comQ

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

September 9 at 9:15 AM | globenewswire.com

Silo Pharma’s lead asset SPC-15, an intranasal 5-HT4 receptor agonist targeting post-traumatic stress disorder receives Canadian patent

August 20, 2026 | pharmabiz.comP

Silo Pharma Gets Canadian Patent Allowance for Stress Disorder Treatment

August 20, 2026 | finance.yahoo.com

Silo Pharma Acquires Digital Assets via Stock Issuance

August 19, 2026 | tipranks.com

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

August 18, 2026 | globenewswire.com

Silo Pharma Granted European Patent Covering Novel PTSD Therapy

August 10, 2026 | markets.businessinsider.com

Silo Pharma Announces European Patent Grant for SPC-15 PTSD Prevention Therapy

August 10, 2026 | quiverquant.comQ

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

August 6, 2026 | globenewswire.com

Silo Pharma Advances QwikAgents Commercial Launch and SPC-15 Development

July 21, 2026 | quiverquant.comQ

Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program

July 21, 2026 | globenewswire.com

Is Silo Pharma, Inc. (SILO) Stock an AI Opportunity After NVIDIA Partnership Boosts QwikAgents Platform?

July 15, 2026 | insidermonkey.com

Silo Pharma’s QwikAgents joins AMD AI developer program to advance AI agent platform

July 14, 2026 | msn.com

Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership

July 14, 2026 | benzinga.com

Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform

July 14, 2026 | globenewswire.com

CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall

July 10, 2026 | finance.yahoo.com

Silo Pharma Sinks on Stock Sale

July 10, 2026 | baystreet.ca

Silo Pharma shares slide after announcing up to $11.7 million private placement (SILO)

July 10, 2026 | msn.com

Silo Pharma Announces $4 Million Private Placement with Up to Approximately $7.7 Million in Potential Additional Gross Proceeds from Warrants

July 10, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO, QNRX, DARE, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

$1.98 -0.14 (-6.60%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.01 +0.03 (+1.62%)

As of 09/11/2026 07:55 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Dare Bioscience NASDAQ:DARE

$0.71 +0.00 (+0.13%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.72 +0.02 (+2.69%)

As of 09/11/2026 07:42 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Quoin Pharmaceuticals NASDAQ:QNRX

$6.79 -0.11 (-1.59%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.85 +0.06 (+0.88%)

As of 09/11/2026 05:07 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Silo Pharma NASDAQ:SILO

$2.10 0.00 (0.00%)

Closing price 09/11/2026 03:59 PM Eastern

Extended Trading

$2.13 +0.03 (+1.48%)

As of 09/11/2026 07:49 PM Eastern

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SILO, QNRX, DARE, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SILO, QNRX, DARE, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SILO, QNRX, DARE, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO, QNRX, DARE, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

Dare Bioscience NASDAQ:DARE

Quoin Pharmaceuticals NASDAQ:QNRX

Silo Pharma NASDAQ:SILO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SILO, QNRX, DARE, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SILO, QNRX, DARE, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SILO, QNRX, DARE, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SILO, QNRX, DARE, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

Dare Bioscience NASDAQ:DARE

Quoin Pharmaceuticals NASDAQ:QNRX

Silo Pharma NASDAQ:SILO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools